BiomX (NYSEAMERICAN:PHGE) Earns “Buy” Rating from HC Wainwright

BiomX (NYSEAMERICAN:PHGE)‘s stock had its “buy” rating reaffirmed by HC Wainwright in a report issued on Wednesday,Benzinga reports. They currently have a $2.00 price target on the stock. HC Wainwright’s price target would indicate a potential upside of 170.45% from the stock’s current price.

BiomX Stock Down 6.4 %

Shares of NYSEAMERICAN:PHGE opened at $0.74 on Wednesday. The stock has a market cap of $13.44 million, a P/E ratio of -0.23 and a beta of 1.31. BiomX has a fifty-two week low of $0.48 and a fifty-two week high of $8.55.

BiomX Company Profile

BiomX Inc, a clinical-stage microbiome company, develops products using natural and engineered phage technologies designed to target and kill specific harmful bacteria. It targets bacteria that affect the appearance of skin, as well as chronic diseases, such as inflammatory bowel diseases (IBD), primary sclerosing cholangitis (PSC), cystic fibrosis (CF), atopic dermatitis, and colorectal cancer (CRC).